A Study of Wearable Devices to Predict Migraines
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT05755945
- Status
- Enrolling By Invitation
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- eHealth Application — OTHERCustom phone application that integrates data from smart watch. Subjects will complete daily "To-Do-Lists" where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache.
Study Details
The purpose of this research is to determine if data from smart devices, including heart rate and movement during sleep and wake times, will be able to track headaches and predict recurrence and exacerbations (make worse). This use of this information may in the future allow patients earlier and more effective treatments if these devices can help predict when the headaches may occur.
Key Dates
- Start date
- Feb 24, 2023
- Status verified
- May 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: Custom Phone eHealth ApplicationSubjects diagnosed with migraine headaches and have had a positive response to prevention treatments for migraine, will wear an Apple Watch whenever possible (including during sleep) and complete application questionnaires on the eHealth application daily.
Primary Outcome Measure
Percentage accuracy of fit with AUC of the ROC (receiver operating characteristics) curve (%) for headache tracking. [ Time Frame: 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Minnesota | Rochester | Minnesota | 55905 | - |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)PHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)PHASE3 · Enrolling By Invitation · AbbVie · Huntsville, Alabama
- Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual StimuliRecruiting · University of Minnesota · Minneapolis, Minnesota
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyPHASE4 · Recruiting · Mayo Clinic · Flagstaff, Arizona